SK Chemicals seeks bigger market share in Europe

Published: 2013-02-12 06:58:00

Updated: 2013-02-12 06:58:00

SK Chemicals, Korea’s leading pharmaceutical and chemical products manufacturer, is gearing up to boost its marketing activities in Europe with its dementia patch treatment, named SID710 (rivastigmine), was approved by German health authorities (BfArM).

The company said Wednesday that it plans...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK